NCT01894243 - Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2014

Primary Completion Date

November 29, 2016

Study Completion Date

March 30, 2017

Conditions

Solid Tumours

Interventions

DRUG

Olaparib tablet dosing

Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Trial Locations (12)

Research Site, Dijon

Research Site, Bordeaux

Research Site, Bordeaux

Research Site, Grenoble

Research Site, Lyon

Research Site, Paris

Research Site, Brno

Research Site, Amsterdam

Research Site, Maastricht

Research Site, Seoul

Research Site, London

Research Site, Sutton